Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma

Cancer Science

Volumn 102, Issue 9, 2011, Pages 1742-1747

  Sekine, Shigeki ^a   Ogawa, Reiko ^a   Ojima, Hidenori ^a   Kanai, Yae ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILIRUBIN; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL 7ALPHA MONOOXYGENASE; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 4; PROTEIN SLCO1B3; UNCLASSIFIED DRUG;

ABCC4 GENE; ARTICLE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILIRUBIN METABOLISM; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

BETA CATENIN; BILE ACIDS AND SALTS; CARCINOMA, HEPATOCELLULAR; CHOLESTASIS; HUMANS; LIVER NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT;

EID: 80051806849     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01990.x     Document Type: Article

References (36)

1. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008; 65: 2461-83.
2. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72: 137-74.
3. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-93.
4. Huang W, Ma K, Zhang J et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006; 312: 233-6.
5. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007; 67: 863-7.
6. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007; 28: 940-6.
7. Audard V, Grimber G, Elie C et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 2007; 212: 345-52.
8. Sekine S, Ogawa R, Ojima H, Kanai Y. Overexpression of AMACR is associated with CTNNB1 mutations in hepatocellular carcinomas. Histopathology 2011; 58: 712-9.
9. Miyoshi Y, Iwao K, Nagasawa Y et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998; 58: 2524-7.
10. de La Coste A, Romagnolo B, Billuart P et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95: 8847-51.
11. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006; 281: 22429-33.
12. Morin PJ, Sparks AB, Korinek V et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-90.
13. Sekine S, Lan BY, Bedolli M, Feng S, Hebrok M. Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology 2006; 43: 817-25.
14. Schwarz M, Wright AC, Davis DL, Nazer H, Bjorkhem I, Russell DW. The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J Clin Invest 2000; 106: 1175-84.
15. Lu TT, Makishima M, Repa JJ et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6: 507-15.
16. Goodwin B, Jones SA, Price RR et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-26.
17. Su LK, Abdalla EK, Law CH, Kohlmann W, Rashid A, Vauthey JN. Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. Cancer 2001; 92: 332-9.
18. Zucman-Rossi J, Jeannot E, Nhieu JT et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43: 515-24.
19. Lustig B, Jerchow B, Sachs M et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002; 22: 1184-93.
20. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22: 1172-83.
21. Behari J, Yeh TH, Krauland L et al. Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol 2010; 176: 744-53.
22. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278: G156-64.
23. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-8.
24. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 276: 9626-30.
25. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 2003; 371: 897-905.
26. Abe T, Unno M, Onogawa T et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001; 120: 1689-99.
27. Zelcer N, Reid G, Wielinga P et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 2003; 371: 361-7.
28. Kang TW, Kim HJ, Ju H et al. Genome-wide association of serum bilirubin levels in Korean population. Hum Mol Genet 2010; 19: 3672-8.
29. Sanna S, Busonero F, Maschio A et al. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet 2009; 18: 2711-8.
30. Narita M, Hatano E, Arizono S et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-8.
31. Kitao A, Zen Y, Matsui O et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging - correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-26.
32. Tsuboyama T, Onishi H, Kim T et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 824-33.
33. Zucker SD, Goessling W, Ransil BJ, Gollan JL. Influence of glutathione S-transferase B (ligandin) on the intermembrane transfer of bilirubin. Implications for the intracellular transport of nonsubstrate ligands in hepatocytes. J Clin Invest 1995; 96: 1927-35.
34. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4: 815-8.
35. Libra A, Fernetti C, Lorusso V et al. Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther 2006; 319: 809-17.
36. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009; 5: 703-29.